ProShare Advisors’s Tourmaline Bio TRML Stock Holding History

ProShare Advisors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,048	Closed	-$160K	–	2300
2021 Q4	$160K	Buy	+1,048	New	+$155K	﹤0.01%	2109

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

ProShare Advisors's TRML Position: Q1 2022 in Review

ProShare Advisors sold out of Tourmaline Bio (TRML) in Q1 2022, closing a stake of 1,048 shares — an estimated $160K sold.

ProShare Advisors first reported a position in TRML in Q4 2021 and held it in 1 quarter. The position peaked at $160K in Q4 2021. 51 funds tracked by Wall St. Rank hold TRML as of Q1 2022.

ProShare Advisors reported no remaining Tourmaline Bio position as of Q1 2022 after selling out during the quarter.
ProShare Advisors sold 1,048 Tourmaline Bio shares in Q1 2022, an estimated $160K.
ProShare Advisors first reported a position in Tourmaline Bio in Q4 2021 and held it in 1 quarter.
ProShare Advisors's Tourmaline Bio position peaked at $160K in Q4 2021.
51 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.